A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Results (n=358) of analysis assessing relationship between Ctrough and efficacy and safety, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 May 2017 According to a Novartis media release data from this study will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Mar 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Apr 2019, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top